SEARCH

SEARCH BY CITATION

References

  • 1
    Bardsley-Elliot A, Plosker GL. Nelfinavir: An update on its use in HIV infection. Drugs 2000; 59: 581620.
  • 2
    Pai VB, Nahata MC. Nelfinavir mesylate: a protease inhibitor. Ann Pharmacother 1999; 33: 325339.
  • 3
    Powderly WG, Tebas P. Nelfinavir, a new protease inhibitor: early clinical results. AIDS 1999; 13 (Suppl. 1): S41S48.
  • 4
    Zhang KE, Wu E, Patick AK et al. Circulating metabolites of the human immunodeficiency virus protease inhibitor nelfinavir in humans: Structural identification, levels in plasma, and antiviral activities. Antimicrob Agents Chemother 2001; 45: 10861093.
  • 5
    Herforth C, Stone JA, Jayewardene AL et al. Determination of nelfinavir free drug concentrations in plasma by equilibrium dialysis and liquid chromatography/tandem mass spectroscopy: Important factor for method optimization. Eur J Pharm Sci 2002; 15: 185195.
  • 6
    Patick AK, Mo H, Markowitz M et al. Antiviral and resistance studies of AG1343, an orally bioavailable inhibitor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996; 40: 292297.
  • 7
    Souich P, Verges J, Erill S. Plasma protein binding and pharmacological response. Clin Pharmacokinet 1993; 24: 435440.
  • 8
    Kageyama S, Anderson BD, Hoesterey BL et al. Protein binding of human immunodeficiency virus protease inhibitor KNI-272 and alteration of its in vitro antiretroviral activity in the presence of high concentration of proteins. Antimicrob Agents Chemother 1994; 38: 11071111.
  • 9
    Bilello JA, Bilello PA, Prichard M. Reduction of the in vitro activity of A77003, an inhibitor of human immunodeficiency virus protease, by human serum α-1 acid glycoprotein. J Infect Dis 1995; 171: 546551.
  • 10
    Livingston DJ, Pazhanisamy S, Porter DJT. Weak binding of VX-478 to human plasma proteins and implications for anti-human immunodeficiency virus therapy. J Infect Dis 1995; 172: 12381245.
  • 11
    Lazdins JK, Mestan J, Goutte G et al. In vitro effect of α-1 acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors. J Infect Dis 1997; 175: 10631070.
  • 12
    Bilello JA, Bilello PA, Stellrecht K et al. Human serum α-1 acid glycoprotein reduces uptake, intracellular concentration, and antiviral activity of A-80987, an inhibitor of the human immunodeficiency virus type 1 protease. Antimicrob Agents Chemother 1996; 40: 14911497.
  • 13
    Barry M, Gibbons S, Back D et al. Protease inhibitors in patients with HIV disease. Clin Pharmacokinet 1997; 32: 194209.
  • 14
    Øie S, Jacobson MA, Abrams DI. α-1 acid glycoprotein levels in AIDS patients before and after short-term treatment with zidovudine (ZDV). J Acquir Immune Defic Syndr 1993; 6: 531533.
  • 15
    Veronese L, Rautaureau J, Sadler BM et al. Single-dose pharmacokinetics of amprenavir, a human immunodeficiency virus type 1 protease inhibitor, in subjects with normal or impaired hepatic function. Antimicrob Agents Chemother 2000; 44: 821826.
  • 16
    Kawachi A, Motoya T, Miyashita M et al. Different effect of nonsteroidal anti-inflammatory drugs on the protein binding of warfarin and its enantiomers. J Appl Ther Res 1998; 2: 101108.
  • 17
    Agemura H, Motoya T, Yamada K. Different effects of high protein-binding drugs on the binding of phenytoin, valproic acid, and salicylic acid to human serum proteins. J Appl Ther Res 2000; 3: 1930.
  • 18
    Wright JD, Boudinot FD, Ujhelyi MR. Measurement and analysis of unbound drug concentrations. Clin Pharmacokinet 1996; 30: 445462.
  • 19
    Kremer JMH, Wilting J, Janssen LHM. Drug binding to human α-1 acid glycoprotein in health and disease. Pharmacol Rev 1988; 40: 147.
  • 20
    Kiriyama A, Nishiura T, Ishino M et al. Binding characteristics of KNI-272 to plasma proteins, a new potent tripeptide HIV protease inhibitor. Biopharm Drug Disposit 1996; 17: 739751.
  • 21
    Merry C, Barry MG, Mulcahy F et al. The pharmacokinetics of combination therapy with nelfinavir plus nevirapine. AIDS 1998; 12: 11631167.
  • 22
    Sadler BM, Gillotin C, Lou Y et al. In vivo effect of α-1 acid glycoprotein on pharmacokinetics of amprenavir, a human immunodeficiency virus protease inhibitor. Antimicrob Agents Chemother 2001; 45: 852856.
  • 23
    Chaput AJ, D'Ambrosio R, Morse GD. In vitro protein-binding characteristics of delavirdine and its N-dealkylated metabolite. Antiviral Res 1996; 32: 8189.